Product Code: ETC044707 | Publication Date: Jul 2023 | Updated Date: Jan 2024 | Product Type: Report | |
Publisher: 6Wresearch | No. of Pages: 70 | No. of Figures: 35 | No. of Tables: 5 | |
The Singapore Companion Animal Specialty Drugs market is expected to register a CAGR of 5.6% during the forecast period (2020-2026). The companion animal specialty drugs market in Singapore has been growing consistently over the past few years, due to factors such as an increase in pet ownership and rising demand for treatments that ensure comfort and wellness of pets. Moreover, increasing investments from major players in research & development activities are further driving the growth of this market.
Rising Pet Ownership: As per Statistics Singapore, there were approximately 506 thousand owned pets in 2018 which includes cats, dogs, birds and other small animals like hamsters or guinea pigs ETC, indicating an increased trend towards pet adoption among households across the country. This rising pet ownership is providing ample opportunities for veterinary drug manufacturers by creating higher demand for companion animal specialty drugs.Increasing Investments In Research And Development Activities By Major Players: Major players within this industry such as Elanco Animal Health Incorporated have been investing heavily into R&D activities aimed at developing innovative products with improved efficacy and safety profiles. These initiatives have enabled them to strengthen their product portfolio thereby leading to higher revenue generation opportunities from both domestic as well international markets including Singapore.
Stringent Regulatory Framework For Approval Of Veterinary Drugs: Drug approval procedures involve stringent regulatory requirements which may hinder approvals and manufacturers??? ability to bring their products quickly into markets without compromising on quality standards set by local authorities concerning safety issues related pharmaceuticals available in Singapore retail outlets or online stores; thereby limiting growth prospects of this market especially for new entrants who may find it difficult to meet these guidelines within shorter timeframes.
Some key player operating within this space include Bayer AG, Boehringer Ingelheim International GmbH, Merck & Co Inc., Novartis AG, Sanofi S A ETC
The impact of Covid-19 pandemic on global economies has resulted into reduced disposable income levels among consumers adversely impacting their purchasing power; thus affecting sales volumes witnessed within veterinary drug segment including those pertaining specifically towards companion animal specialization drugs.Additionally, changes implemented under lockdown regulations such as closure/restriction imposed upon certain distribution channels had impacted number orders placed ; resulting into disruption supply chain networks globally.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Singapore Companion Animal Specialty Drugs Market Overview |
3.1 Singapore Country Macro Economic Indicators |
3.2 Singapore Companion Animal Specialty Drugs Market Revenues & Volume, 2020 & 2030F |
3.3 Singapore Companion Animal Specialty Drugs Market - Industry Life Cycle |
3.4 Singapore Companion Animal Specialty Drugs Market - Porter's Five Forces |
3.5 Singapore Companion Animal Specialty Drugs Market Revenues & Volume Share, By Product Types, 2020 & 2030F |
3.6 Singapore Companion Animal Specialty Drugs Market Revenues & Volume Share, By Distribution Channel, 2020 & 2030F |
4 Singapore Companion Animal Specialty Drugs Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Singapore Companion Animal Specialty Drugs Market Trends |
6 Singapore Companion Animal Specialty Drugs Market, By Types |
6.1 Singapore Companion Animal Specialty Drugs Market, By Product Types |
6.1.1 Overview and Analysis |
6.1.2 Singapore Companion Animal Specialty Drugs Market Revenues & Volume, By Product Types, 2020-2030F |
6.1.3 Singapore Companion Animal Specialty Drugs Market Revenues & Volume, By Anti-Inflammatory Drugs, 2020-2030F |
6.1.4 Singapore Companion Animal Specialty Drugs Market Revenues & Volume, By Vaccines, 2020-2030F |
6.1.5 Singapore Companion Animal Specialty Drugs Market Revenues & Volume, By Antibiotics, 2020-2030F |
6.1.6 Singapore Companion Animal Specialty Drugs Market Revenues & Volume, By Animal Feed Additives, 2020-2030F |
6.1.7 Singapore Companion Animal Specialty Drugs Market Revenues & Volume, By Parasiticides, 2020-2030F |
6.1.8 Singapore Companion Animal Specialty Drugs Market Revenues & Volume, By Skin Care Products, 2020-2030F |
6.2 Singapore Companion Animal Specialty Drugs Market, By Distribution Channel |
6.2.1 Overview and Analysis |
7 Singapore Companion Animal Specialty Drugs Market Import-Export Trade Statistics |
7.1 Singapore Companion Animal Specialty Drugs Market Export to Major Countries |
7.2 Singapore Companion Animal Specialty Drugs Market Imports from Major Countries |
8 Singapore Companion Animal Specialty Drugs Market Key Performance Indicators |
9 Singapore Companion Animal Specialty Drugs Market - Opportunity Assessment |
9.1 Singapore Companion Animal Specialty Drugs Market Opportunity Assessment, By Product Types, 2020 & 2030F |
9.2 Singapore Companion Animal Specialty Drugs Market Opportunity Assessment, By Distribution Channel, 2020 & 2030F |
10 Singapore Companion Animal Specialty Drugs Market - Competitive Landscape |
10.1 Singapore Companion Animal Specialty Drugs Market Revenue Share, By Companies, 2023 |
10.2 Singapore Companion Animal Specialty Drugs Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |